PCMC
CSTL icon

Planning Capital Management Corporation’s Castle Biosciences CSTL Stock Holding History

Planning Capital Management Corporation’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$58 Buy
2
+1
+100% +$25 ﹤0.01% 736
2024
Q2 		$22 Buy
+1
New +$22 ﹤0.01% 703

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Planning Capital Management Corporation's CSTL Position: Q3 2024 in Review

Planning Capital Management Corporation increased its Castle Biosciences (CSTL) stake by 100% in Q3 2024, buying an estimated $25 and bringing the position to 2 shares worth $58. The position accounts for ﹤0.01% of the portfolio, ranked #736.

Planning Capital Management Corporation first reported a position in CSTL in Q2 2024 and has held it in 2 quarters since. 185 funds tracked by Wall St. Rank hold CSTL as of Q3 2024.

  • Planning Capital Management Corporation held 2 shares of Castle Biosciences worth $58 as of Q3 2024.
  • Planning Capital Management Corporation bought 1 Castle Biosciences share in Q3 2024, an estimated $25.
  • Castle Biosciences made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #736 holding.
  • Planning Capital Management Corporation first reported a position in Castle Biosciences in Q2 2024 and has held it in 2 quarters since.
  • 185 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.